Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.

被引：0
|
作者：
Weber, Donna
Wang, Michael
Chen, Christine
Belch, Andrew
Stadtmauer, Edward A.
Niesvisky, Ruben
Yu, Zhinuan
Olesnyckyj, Marta
Zeldis, Jerome
Knight, Robert D.
Dimopoulos, Meletios
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Cornell Univ, Presbyterian Hosp, New York, NY USA
[6] Celgene Corp, Summit, NJ USA
[7] Univ Athens, Sch Med, Dept Therapeut, Kifisia, Greece
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3547
引用
收藏
页码：1012A / 1013A
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)
    Cavo, Michele
    Corradini, Paolo
    Di Raimondo, Francesco
    Petrini, Mario
    Cafro, Anna Maria
    di Toritto, Tommaso Caravita
    Offidani, Massimo
    Semenzato, Gianpietro
    Zambello, Renato
    Lazzaro, Antonio
    Petrucci, Maria Teresa
    Rodeghiero, Francesco
    Simcock, Mathew
    Slaughter, Ana
    Herring, Jennifer
    Peluso, Teresa
    Palumbo, Antonio
    BLOOD, 2015, 126 (23)
  • [32] PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: MM-003 SUBANALYSIS OF ELDERLY PATIENTS (> 65 AND > 70 YEARS OF AGE)
    Weisel, K. C.
    San Miguel, J. F.
    Song, K. W.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Moreau, P.
    Banos, A.
    Oriol, A.
    Garderet, L.
    Cavo, M.
    Ivanova, V.
    Alegre, A.
    Martinez Lopez, J.
    Chen, C. I.
    Knop, S.
    Yu, X.
    Watkins, L.
    Sternas, L.
    Jacques, C.
    Zaki, M. H.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2014, 99 : 364 - 365
  • [33] The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in refractory or relapsed and refractory multiple myeloma
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Cavo, Michele
    Corradini, Paolo
    Delforge, Michel
    Morgan, Gareth J.
    Hansson, Markus
    Palumbo, Antonlo
    Oclo, Enrique M.
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Leupin, Nicolas
    Nikolova, Zariana G.
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT
    Sonneveld, P.
    Weisel, K.
    van de Donk, N.
    Ramasamy, K.
    Gamberi, B.
    Streetly, M.
    Offidani, M.
    Bridoux, F.
    de la Rubia, J.
    Kueenburg, E.
    Collins, S.
    Di Micco, A.
    Rosettani, B.
    Bacon, P.
    Dimopoulos, M.
    HAEMATOLOGICA, 2017, 102 : 113 - 114
  • [35] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
    Hagiwara, Shotaro
    Okamoto, Shinichiro
    Matsue, Kosei
    Iida, Shinsuke
    Sunami, Kazutaka
    Komeno, Takuya
    Suzuki, Kenshi
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Tobinai, Kensei
    Chou, Takaaki
    Kaneko, Hitomi
    Iwasaki, Hiromi
    Uemura, Chie
    Tamakoshi, Hiromi
    Zaki, Mohamed H.
    Doerr, Thomas
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    BLOOD, 2015, 126 (23)
  • [36] Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study.
    Lee, SJ
    Richardson, PG
    Sonneveld, P
    Schuster, M
    Irwin, D
    Massaro, J
    Crawford, B
    Dhawan, R
    Gupta, S
    Anderson, KC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 568S - 568S
  • [37] Results From The CC-220-MM-001 Dose-Expansion Phase Of Iberdomide Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Popat, Rakesh
    Hulin, Cyrille
    Jagannath, Sundar
    Oriol, Albert
    Richardson, Paul G.
    Facon, Thierry
    Weisel, Katja
    Larsen, Jeremy T.
    Minnema, Monique
    Abdallah, Al-Ola
    Badros, Ashraf Z.
    Knop, Stefan
    Stadtmauer, Edward A.
    Chen, Min
    Nguyen, Tuong Vi
    Amin, Alpesh
    Peluso, Teresa
    van de Donk, Niels W. C. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 38 - 39
  • [38] Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
    Morgan, Gareth
    Palumbo, Antonio
    Dhanasiri, Sujith
    Lee, Dawn
    Weisel, Katja
    Facon, Thierry
    Delforge, Michel
    Oriol, Albert
    Zaki, Mohamed
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Akehurst, Ron
    Offner, Fritz
    Dimopoulos, Meletios A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 820 - 823
  • [39] THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS
    Hou, J.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Zhou, D.
    Yu, L.
    Ke, X.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Chen, N.
    Mei, J.
    Wang, J.
    HAEMATOLOGICA, 2013, 98 : 341 - 341
  • [40] THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Palumbo, A.
    Corradini, P.
    Cavo, M.
    Delforge, M.
    Weisel, K.
    Ocio, E.
    Di Raimondo, F.
    Oriol, A.
    Simcock, M.
    Miller, N.
    Slaughter, A.
    Peluso, T.
    Sternas, L.
    Zaki, M.
    Moreau, P.
    HAEMATOLOGICA, 2015, 100 : 83 - 83
12345